Derma Sciences, Inc (DSCI)

[mlkrborn]

Derma Sciences meeting with FDA supports initiation of phase 3 studies with DSC127 in diabetic foot ulcers (DSCI) 8.86 : Co announced that it has discussed the results of the Company's Phase 2 clinical study of the investigational drug DSC127 for the treatment of diabetic foot ulcers with the FDA, and that the FDA has agreed that the drug's development program to date supports the initiation of Phase 3 pivotal clinical studies. Derma Sciences has received guidance from the FDA on the design of Phase 3 trials and other clinical activities, which will allow the Company to adjust the sequence of planned studies, including toxicology studies, for potentially more cost-effective and efficient Phase 3 trials than had previously been contemplated. Initiation of the Phase 3 clinical trials is expected in the second half of 2012.